A case report of treatment with pegylated interferon alpha for lamivudine-resistant chronic hepatitis B virus infection / 대한간학회지
The Korean Journal of Hepatology
;
: 513-518, 2008.
Article
in Korean
| WPRIM
| ID: wpr-147556
ABSTRACT
The wide use of lamivudine in chronic hepatitis B has produced a monotonic increase in patients with lamivudine resistance. Therefore, treating lamivudine resistance in chronic hepatitis B is a major concern in clinical practice for the treatment of hepatitis B virus (HBV). There is conflicting evidence on the outcome of pegylated interferon alpha (PEG-IFN alpha) therapy against lamivudine-resistant HBV, which is due to mutations in the YMDD motif. We experienced a patient with chronic hepatitis B who was successfully treated with PEG-IFN alpha-2a after the development of virologic and biochemical breakthrough during lamivudine therapy. Virologic breakthrough was associated with the emergence of YMDD mutants 48 months after starting lamivudine therapy. Treatment with PEG-IFN alpha-2a for 12 months resulted in an undetectable serum level of HBV DNA and the resolution of hepatitis, and the virologic response was maintained over 16 months after cessation of PEG-IFN alpha-2a.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Antiviral Agents
/
Polyethylene Glycols
/
DNA, Viral
/
Lamivudine
/
Hepatitis B, Chronic
/
Drug Resistance, Viral
/
Alanine Transaminase
/
Interferon alpha-2
/
Liver
Limits:
Adult
/
Humans
/
Male
Language:
Korean
Journal:
The Korean Journal of Hepatology
Year:
2008
Type:
Article
Similar
MEDLINE
...
LILACS
LIS